Literature DB >> 7031974

Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels.

E H Walters, A Cockroft, T Griffiths, K Rocchiccioli, B H Davies.   

Abstract

Salbutamol solution is usually administered by nebuliser in a dose of 5 mg. Little evidence exists that this is the optimal dose for bronchodilatation or that this dose is without side-effects. Twelve patients with asthma were given increasing doses of salbutamol 1.5 mg, 3.0 mg, 7.5 mg, and placebo. Treatments were administered twice daily for four days in a double-blind manner. Measurements of ventilatory capacity, pulse rate, and tremor were recorded before and for three hours after treatment. There was a significant dose-related response for FEVI and peak flow rate. There was also a significant dose-related response in pulse rate and tremor. The incidence of palpitations was similarly related to dose. Plasma levels of salbutamol were measured before and after treatment with salbutamol and showed a dose related increase in salbutamol absorption which begins to be evident after the 3.0 mg dose. Three milligrams of salbutamol nebuliser solution may be an optimal dose, producing satisfactory bronchodilatation but fewer side-effects related to systemic absorption.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031974      PMCID: PMC471656          DOI: 10.1136/thx.36.8.625

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  4 in total

1.  Comparison of intravenous and nebulised salbutamol in initial treatment of severe asthma.

Authors:  P Lawford; B J Jones; J S Milledge
Journal:  Br Med J       Date:  1978-01-14

2.  Salbutamol and isoproterenol. A double-blind trial to compare bronchodilator and cardiovascular activity.

Authors:  A E Tattersfield; M W McNicol
Journal:  N Engl J Med       Date:  1969-12-11       Impact factor: 91.245

3.  Intravenous or inhaled salbutamol in severe acute asthma?

Authors:  S Williams; A Seaton
Journal:  Thorax       Date:  1977-10       Impact factor: 9.139

4.  Quantitative determination of salbutamol in plasma, as either its trimethylsilyl or t-butyldimethylsilyl ether, using a stable isotope multiple ion recording technique.

Authors:  L E Martin; J Rees; R J Tanner
Journal:  Biomed Mass Spectrom       Date:  1976-08
  4 in total
  10 in total

1.  Nebulisers for asthma.

Authors:  M J Ward
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

2.  Home nebulisers for airflow limitation.

Authors:  G M Cochrane; J G Prior; P J Rees
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-01

Review 3.  Adrenergic drugs.

Authors:  C W Bierman
Journal:  Clin Rev Allergy       Date:  1983-03

4.  Dosage and delivery of nebulised beta agonists in hospital.

Authors:  J N Stainforth; R A Lewis; A E Tattersfield
Journal:  Thorax       Date:  1983-10       Impact factor: 9.139

5.  Nebulised salbutamol and angina.

Authors:  E Neville; P A Corris; J Vivian; S Nariman; G J Gibson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-18

6.  Cardiovascular and biochemical responses to nebulised salbutamol in normal subjects.

Authors:  S R Smith; C Ryder; M J Kendall; R Holder
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

Review 7.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

8.  Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; R A Brown; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

Review 9.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.